Serpin Pharma and HekaBio Sign Term Sheet for Groundbreaking Neuropathy Treatment

Serpin Pharma, a Virginia-based biopharmaceutical company, and HekaBio, headquartered in Tokyo, Japan, have signed a term sheet to develop and commercialize SP163M, a novel peptide drug for preventing chemotherapy-induced peripheral neuropathy (CIPN).

SP163M, a groundbreaking discovery by Serpin Pharma, is set to revolutionize pain management. This novel therapy protects nerves from the damaging effects of neurotoxic chemotherapy drugs, facilitates nerve repair, and alleviates pain. For cancer patients suffering from neuropathy as a side effect of chemotherapy, SP163M offers a critically needed solution. The development of neuropathy often necessitates reducing planned chemotherapy regimens, which may affect cancer outcomes. Preventative therapy could be lifesaving for these patients.

As part of this strategic alliance, HekaBio will spearhead the commercialization of SP163M in critical markets, including Japan, Korea, Taiwan, Australia, ASEAN, the Middle East (excluding Israel), and North Africa. This collaboration integrates Serpin Pharma’s prowess in peptide therapeutics with HekaBio’s strong presence in the Asian and Australian markets. HekaBio’s strategic investment in Serpin Pharma, along with milestone and royalty payments, underscores the mutual commitment to the success of this innovative therapy.

Dr. Cohava Gelber, Founder, Executive Chairperson, and CEO of Serpin Pharma, expressed enthusiasm about the collaboration: “We are thrilled to partner with HekaBio to bring this revolutionary therapy to cancer patients. SP163M can potentially significantly improve the quality of life for those undergoing chemotherapy.”

Rob Claar, the CEO of HekaBio, stated: “Our collaboration with Serpin Pharma is inspiring. By combining our complementary capabilities, we aim to deliver a game-changing treatment option for cancer patients suffering from CIPN.”

This partnership marks a significant step towards addressing the unmet medical needs for effective CIPN treatments. As the companies advance their development and commercialization plans, cancer patients in the specified regions may soon have access to this innovative therapy.

W&M Undergrads expand the chemical toolbox for cancer drugs

Thanks to modern therapies, a cancer diagnosis is no longer an automatic death sentence. But many patients still suffer from unwanted side effects and limited efficacy. In a recent Bioconjugate Chemistry publication, William & Mary researchers designed an antibody-drug conjugate (ADC) with the potential to improve the potency and decrease the cost of currently approved cancer drugs. Like …

03/17/2026

AgroSpheres and Wilbur-Ellis® Announce California Approval of FUN-THYME™

AgroSpheres and Wilbur-Ellis today announced that FUN-THYME, a broad-spectrum biofungicide co-developed by the two companies, has been approved for use in California. With demonstrated effectiveness on grapes, berries, apples, cherries, tomatoes and almonds, the new registration unlocks access for California growers. As the largest specialty crop producer in the United States, California is a defining …

03/16/2026

Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics that target toxic soluble amyloid b oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for a private placement of approximately $35.75 …

News